Dyne Therapeutics, Inc., a leading clinical-stage biotech company dedicated to developing innovative therapeutics for individuals affected by genetically driven muscle diseases, has announced plans to release new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIVER clinical trials. The company will host a virtual investor event on May 20, 2024, at 8:00 a.m. ET to discuss these groundbreaking results.
The ACHIEVE and DELIVER trials are designed to evaluate Dyne Therapeutics’ cutting-edge muscle disease treatments, which have the potential to significantly improve the lives of patients living with these debilitating conditions. The upcoming data release is expected to provide valuable insights into the safety and effectiveness of these novel therapies.
